Literature DB >> 12368275

Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction.

Elizabeth K Brint1, Katherine A Fitzgerald, Philip Smith, Anthony J Coyle, Jose-Carlos Gutierrez-Ramos, Padraic G Fallon, Luke A J O'Neill.   

Abstract

T1/ST2 is a member of the interleukin (IL)-1 receptor superfamily, possessing three immunoglobulin domains extracellularly and a Toll/IL1R (TIR) domain intracellularly. The ligand for T1/ST2 is not known. T1/ST2 is expressed on Type 2 T helper (Th2) cells, and its role appears to be in the regulation of Th2 cell function. Here, we have investigated T1/ST2 signal transduction, using either transient overexpression of T1/ST2 or a cross-linking monoclonal antibody to activate cells. We demonstrate that T1/ST2 does not activate the transcription factor NF-kappaB when overexpressed in murine thymoma EL4 cells, or in the mast cell line P815 treated with the anti-T1/ST2 antibody. However, a chimera comprising the extracellular domain of the type 1 IL-1 receptor and the intracellular domain of T1/ST2 activates NF-kappaB both by overexpression and in response to IL-1. This artificial activation requires the IL1RAcP recruited via the extracellular portion (IL1R1) of the chimera. T1/ST2 is, however, able to activate the transcription factor activator protein-1 (AP-1), increase phosphorylation of c-Jun, and activate the MAP kinases c-Jun N-terminal kinase (JNK), p42/p44 and p38. Anti-T1/ST2 also induces the selective expression of IL-4 but not IFN-gamma in naive T cells. Importantly, this effect is blocked by prior treatment with the JNK inhibitor SP600125 confirming that JNK as a key effector in T1/ST2 signaling. The lack of effect on NF-kappaB when T1/ST2 is homodimerized identifies T1/ST2 as the first member of the IL-1 receptor superfamily so far studied that is apparently unable to activate NF-kappaB, consistent with evidence indicating the lack of a role for NF-kappaB in Th2 cell function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368275     DOI: 10.1074/jbc.M209685200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Quantitative phosphoproteomic analysis of IL-33-mediated signaling.

Authors:  Sneha M Pinto; Raja Sekhar Nirujogi; Pamela Leal Rojas; Arun H Patil; Srikanth S Manda; Yashwanth Subbannayya; Juan Carlos Roa; Aditi Chatterjee; T S Keshava Prasad; Akhilesh Pandey
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

Review 2.  A toll for T cell costimulation.

Authors:  F Y Liew; M Komai-Koma; D Xu
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Toll-like receptor 2 signalling and inflammation.

Authors:  F Y Liew; M Patel; D Xu
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 4.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

5.  ST2/MyD88 Deficiency Protects Mice against Acute Graft-versus-Host Disease and Spares Regulatory T Cells.

Authors:  Brad Griesenauer; Hua Jiang; Jinfeng Yang; Jilu Zhang; Abdulraouf M Ramadan; Jane Egbosiuba; Khaled Campa; Sophie Paczesny
Journal:  J Immunol       Date:  2019-04-12       Impact factor: 5.422

6.  Didox (3,4-dihydroxybenzohydroxamic acid) suppresses IL-33-induced cytokine production in primary mouse mast cells.

Authors:  Heather L Caslin; Jamie Josephine Avila McLeod; Andrew J Spence; Amina Abdul Qayum; Elizabeth Motunrayo Kolawole; Marcela T Taruselli; Anuya Paranjape; Howard L Elford; John J Ryan
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

7.  Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33.

Authors:  Tatjana Pecaric-Petkovic; Svetlana A Didichenko; Sacha Kaempfer; Nicole Spiegl; Clemens A Dahinden
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

Review 8.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

9.  Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the anti-inflammatory limb of the immune response.

Authors:  Tamara Stampalija; Roberto Romero; Steven J Korzeniewski; Piya Chaemsaithong; Jezid Miranda; Lami Yeo; Zhong Dong; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2013-06-25

Review 10.  The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.

Authors:  Cem Gabay; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.